HMG20B Antikörper

Produktnummer ABIN272257

Produktdetails anti-HMG20B Antikörper

Target: HMG20B (High Mobility Group 20B (HMG20B))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HMG20B Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Spezifität: This antibody detects endogenous levels of BRAF35 protein. (region surrounding Thr29)

Kreuzreaktivität (Details): Species reactivity (tested):Human.

Aufreinigung: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen

Reinheit: > 95 % pure by SDS-PAGE

Anwendungsinformationen

Applikationshinweise: ELISA: 1: 20000approx. 1: 40000. WB: 1: 500approx. 1: 1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1,0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2., 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: DO NOT FREEZE!

Lagerung: 4 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C.

Details zu HMG20B

Target: HMG20B (High Mobility Group 20B (HMG20B))

Andere Bezeichnung: SMARCE1-Related Protein (HMG20B Produkte)

Synonyme: BRAF25 antikoerper, BRAF35 antikoerper, HMGX2 antikoerper, HMGXB2 antikoerper, PP7706 antikoerper, SMARCE1r antikoerper, SOXL antikoerper, pp8857 antikoerper, AW610687 antikoerper, Hmgx2 antikoerper, Hmgxb2 antikoerper, Smarce1r antikoerper, high mobility group 20 B antikoerper, high mobility group 20B antikoerper, Hmg20b antikoerper, HMG20B antikoerper

Hintergrund: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a 20 kDa complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesinlike coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.Synonyms: BRAF35, BRCA2-associated factor 35, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, HMG20B, HMGX2, HMGXB2, SMARCE1R, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related, Sox-like transcriptional factor, Structural DNA-binding protein BRAF35

Molekulargewicht: approx. 36 kDa

Gen-ID: 10362

NCBI Accession: NP_006330

UniProt: Q9P0W2